APAC CIOOutlook

Advertise

with us

  • Technologies
      • Artificial Intelligence
      • Big Data
      • Blockchain
      • Cloud
      • Digital Transformation
      • Internet of Things
      • Low Code No Code
      • MarTech
      • Mobile Application
      • Security
      • Software Testing
      • Wireless
  • Industries
      • E-Commerce
      • Education
      • Logistics
      • Retail
      • Supply Chain
      • Travel and Hospitality
  • Platforms
      • Microsoft
      • Salesforce
      • SAP
  • Solutions
      • Business Intelligence
      • Cognitive
      • Contact Center
      • CRM
      • Cyber Security
      • Data Center
      • Gamification
      • Procurement
      • Smart City
      • Workflow
  • Home
  • CXO Insights
  • CIO Views
  • Vendors
  • News
  • Conferences
  • Whitepapers
  • Newsletter
  • Awards
Apac
  • Artificial Intelligence

    Big Data

    Blockchain

    Cloud

    Digital Transformation

    Internet of Things

    Low Code No Code

    MarTech

    Mobile Application

    Security

    Software Testing

    Wireless

  • E-Commerce

    Education

    Logistics

    Retail

    Supply Chain

    Travel and Hospitality

  • Microsoft

    Salesforce

    SAP

  • Business Intelligence

    Cognitive

    Contact Center

    CRM

    Cyber Security

    Data Center

    Gamification

    Procurement

    Smart City

    Workflow

Menu
    • Cyber Security
    • Hotel Management
    • Workflow
    • E-Commerce
    • Business Intelligence
    • MORE
    #

    Apac CIOOutlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIOOutlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    The Cancer Diagnostic Firm, Pillar Biosciences Raises $29.7M in Series C Round of Financing

    The Natick, Massachusetts, and Shanghai-based Biosciences Company raised $29.7M from its Series C round of financing  

    The Cancer Diagnostic Firm, Pillar Biosciences Raises $29.7M in Series C Round of Financing

    By

    Apac CIOOutlook | Monday, July 06, 2020

    Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

    The Natick, Massachusetts, and Shanghai-based Biosciences Company raised $29.7M from its Series C round of financing

    Fremont, CA: The cancer diagnostic firm Pillar Biosciences closes a $29.7 Million Series C preferred stock financing round recently. ORI Healthcare Fund led the latest round of funding. The company also launched the CE marketing for its Onco/Reveal Dx lung and colon cancer in vitro diagnostic assay. 

    The Natick, Massachusetts-based assay developer, said it would use these funds to accelerate the widespread extension of its clinical and research-use next-gen sequencing panels and expand its global commercial reach. 

    "We are a strong believer in using NGS tumor testing to make precision medicine the first-line treatment," Simone Song, Senior Partner of ORI Healthcare Fund, said in a statement. "Pillar's Slimamp technology is fast, accurate, user friendly, and cost-effective. We have confidence that Pillar will fulfill an unmet medical need and bring true benefits to cancer patients."

    The Slimamp target enrichment chemistry offers a single tube that is an amplicon-based assay and is also compatible with Illumina, Thermo Fisher Scientific Ion Torrent, and MGI sequencing platforms. Pillar also provides services and bioinformatics tools that allow variant calling. 

    Previously, Pillar had received an $18 million investment from the same ORI Healthcare Fund in 2016 and has earlier signed a co-marketing agreement with BGI subsidiary MGI Tech along with an IVD development partnership contract with Illumina. 

    In 2019, the firm entered a joint venture contract with China Biotech Services Holdings to offer diagnostic products and services to the regions of Hong Kong, Macau, South Korea, and Southeast Asia. The same company, China Biotech Services Holdings, took part in the undisclosed Series B funding round by Pillar. 

    The company's custom product that gained approval from the New York State Department of Health guides the prescription of six varieties of therapies simultaneously, reducing the need for conducting repeat tests, and enables the treatment decisions to be made in 4 days.

    Pillar has also secured distributors in Israel, Hong Kong, Macau, South Korea, and ASEAN countries recently. 

    See also: Top Pharma Machinery Solution Companies

    More in News

    Real-Time Insights Fueling Smarter Brand Strategies

    Real-Time Insights Fueling Smarter Brand Strategies

    Transforming Retail: The Impact of VR and AR in Asia Pacific

    Transforming Retail: The Impact of VR and AR in Asia Pacific

    Enhancing Customer Satisfaction through Omni-Channel Payments

    Enhancing Customer Satisfaction through Omni-Channel Payments

    AI's Role in Apac's Digital Transformation Journey

    AI's Role in Apac's Digital Transformation Journey

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Copyright © 2025 APAC CIOOutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    Home |  CXO Insights |   Whitepapers |   Subscribe |   Conferences |   Sitemaps |   About us |   Advertise with us |   Editorial Policy |   Feedback Policy |  

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/the-cancer-diagnostic-firm-pillar-biosciences-raises-297m-in-series-c-round-of-financing-nwid-7499.html